This 68-year-old black male has had sickle cell disease since childhood and has suffered the typical sickle cell crises that are characterized primarily by bone pain. The patient's longevity is probably attributable to a high percentage of fetal hemoglobin-65% hemoglobin SS by electrophoresis. From age 25, he underwent blood transfusion at approximately 6-month intervals, maintaining a hematocrit of approximately 30%. Sickle cell crises, managed with analgesics and hydration, occurred I to 2 times per year from age 25 to his most recent admission. From ages 28 to 30, the patient developed leg ulcers and acute cholecystitis for which he underwent a sympathectomy and a cholecystectomy, respectively. At age 30, he developed tophaceous gout, which was managed with probenecid. Laboratory findings at that time included a serum uric acid of 10.8 mg/dl and a serum urea nitrogen of 16 mg/dl. A marked defect in urinary concentration-Umax = 320 mOsm/kg-was observed following a 12-hour overnight dehydration test. At age 40, the patient developed angina pectoris as well as congestive heart failure and peripheral edema; his blood pressure was 170/100 mm Hg, and cardiomegaly was evident on chest x-ray. The patient was started on a regimen of digitalis and diuretics.
colchicine, and occasionally indomethacin. During this time, the serum potassium concentration never fell below 6 mEq/liter and ranged as high as 7.8 mEq/Iiter. Because of the persistently high serum potassium concentration, the patient was admitted to the clinical research center for further diagnostic evaluation.
On admission, the physical examination revealed the following: blood pressure, 200/100 mm Hg; pulse, 84/mm and regular; respirations, 16/mm; temperature, 37° C. The skin showed old ulcer disease and stasis dermatitis; the optic fundi had moderate arteriolar narrowing and arteriovenous nicking without hemorrhages or exudates; the neck veins were distended 6 cm above the clavicle at 45°. Moist rales were heard one-third of the way up both lung fields posteriorly; the point of maximal impulse was diffuse in the 6th to 7th intercostal interspaces and 15 cm to the left of the midsternal line; S3 and S4 gallops were present; a Grade IIIIVl systolic ejection murmur was heard at the base and radiated to the lower left sternal border. Abdominal examination revealed no organomegaly or tenderness. Rectal examination was normal and the prostate was enlarged (1+). Examination of the extremities revealed markedly diminished peripheral pulses, tophi over both elbows, and deforming arthritis of the hands and big toes, which had been affected previously with gout. Neurologic examination was unremarkable except for absent reflexes in the lower extremities and decreased sensation below the knees.
Laboratory findings included the following: hematocrit, 28%; WBC, 6800 with a normal differential; reticulocyte count, 1.2%; serum potassium. 7.2 mEq/liter, with a simultaneous plasma potassium of 6.8 mEq/liter; serum sodium, 140 mEqlliter serum chloride, 109 mEq/liter serum bicarbonate, 19 mEq/liter; serum urea nitrogen, 39 mg/dl serum creatinine, 2 mg/dl serum uric acid, II 8 mg/dl serum calcium, 9 mg/dl serum phosphate, 4.7 mg/dl; blood pH, 7.33; carbon dioxide tension, 31 mm Hg; a simultaneous urine pH obtained under oil. 5.1; 24-hour urine protein excretion, 2.4 grams; 24-hour urine uric acid excretion, 500 mg; creatinine clearance, 35 mI/mm. Results of urinalysis revealed; 2 to 5 WBC Additional studies were performed to define the mechanism of the hyperkalemia and these findings will be discussed.
Discussion
Dr. Ralph A. DeFronzo (Associate Professor of Medicine, Yale University School of Medicine, New Haven, Connecticut): This 68-year-old black man is the oldest known living patient with sickle cell disease. Today I plan to discuss only one of his renal and electrolyte problems-hyperkalemia. A full understanding of the etiology and management of this patient's severe hyperkalemia requires a brief review of the normal renal handling of potassium.
Renal potassiuFn handling. Recent studies indicate that the majority of the potassium excreted in the urine is derived from secretion in the distal tubule and collecting duct [1] [2] [3] . Although approximately 600 to 700 mEq of potassium are filtered daiiy by the glomerulus, most potassium is reabsorbed proximally and only approximately 10% remains by the early distal tubule. This fraction remains fixed despite a variety of maneuvers that are known either to increase or decrease the rate of urinary potassium excretion. Approximately 60% of the filtered potassium load is reabsorbed by the accessible portion of the proximal convoluted tubule, and an additional 25% to 30% has been reabsorbed by the time the fluid reaches the first accessible segment of the distal tubule. Although some potassium may be added to the tubular fluid by the ascending loop of Henle [3] , the mid-to-late distal convoluted tubule is the first major site of potassium secretion [1] [2] [3] . Cells of the cortical collecting duct are morphologically similar to those of the distal tubule; it is not surprising therefore that this segment of the collecting duct is also capable of net potassium secretion [3, 4] . Although the contribution of the medullary collecting duct to final potassium excretion remains uncertain, several recent studies have indicated an important role of this nephron segment in renal potassium excretion [5] [6] [7] .
Figure 1 illustrates a model depicting distal tubular potassium secretion using data gathered from micropuncture, microperfusion, and other techniques [3, 8] . This model contains several salient features.
(1) The luminal membrane is electronegative by approximately 50 mV as compared with the pericapillary membrane. (2) An active pump located in the pericapillary membrane transfers potassium into the cell against a large concentration gradient. Once within the cell, the potassium either back diffuses into the capillary blood or enters the tubular lumen, but the electrical gradient, which is lumen negative, favors the net secretion of potassium into the tubular fluid. ( 3) The transport of potassium by the active pump is coupled in some loose fashion to sodium transport, and the activity of the pump appears to be influenced by the enzyme sodium-potassium ATPase. (4) The pump system is dependent on the presence of aldosterone and in the absence of this hormone the ability to secrete potassium is markedly impaired. (5) The activity of the pump is exquisitely sensitive to small changes in the potassium concentration in the pericapillary blood: hyperkalemia provides a potent stimulus to enhanced potassium uptake by the distal tubular cell. Once inside the cell, potassium passively diffuses down the electrochemical gradient into the tubular fluid. (6) An increase in sodium delivery alone and an increase in urine flow independent of sodium delivery stimulate potassium excretion [9] . (7) The activity of the pump is strongly influenced by changes in acid-base status: acute acidosis inhibits, and acute alkalosis stimulates, potassium secretion. (8) A potassium reabsorptive mechanism also must exist in the distal tubule because urinary potassium excretion can approach zero under conditions of severe dietary potassium restriction despite delivery of 5% to 10% of the filtered load to the early distal tubule.
The pathophysiology of the clinical disorders complicated by impaired potassium secretion and, consequently, hyperkalemia follows directly from this model of renal potassium handling. Thus, decreased renal excretion of potassium and the potential for hyperkalemia can result from inadequate so- K dium delivery to the distal nephron; decreased urine flow; a defect in the renin-angiotensin-aldosterone axis; a primary tubular secretory defect; inhibition of the potassium pump; or the presence of renal disease, which directly affects the integrity of the potassium secretory cells located in the distal nephron.
Differential diagnosis of sustained hyperkalernia.
The search for the cause of hyperkalemia can be approached in a logical sequence. Table I lists nine general causes of increased serum potassium levels. Before initiating an extensive investigation, factitious causes should be excluded. In the patient presented today, laboratory error was excluded by repeated plasma determinations. "Pseudohyperkalemia" was excluded by the observation that simultaneous determinations of potassium concentration in serum and plasma agreed within 0.2 mEq/liter and by the normal white blood cell and platelet counts. Acute acidemia is a well-known cause of true hyperkalemia [10] . Two mechanisms are involved: first, acute acidemia inhibits renal potas- were normal, the disturbance in potassium homeostasis cannot be related to an acid-base disorder. Increased input of potassium, from either exogenous or endogenous sources, can also result in hyperkalemia, but the rise in plasma potassium concentration is usually transient unless an underlying defect in renal potassium excretion is present as well [11] . During sustained intravenous potassium chloride infusion, the plasma potassium concentration can rise into the 5.0 to 5.4 mEq/liter range initially, but it returns to normal within 24 to 36 hours because of enhanced renal potassium excretion and increased cellular influx of potassium [12, 13] .
Thus, the persistence of hyperkalemia even in the face of an increased potassium load should suggest an underlying defect in the potassium homeostatic system. In the patient under discussion, no obvious cause of excess potassium input was discernible and, of course, hyperkalemia was sustained for long periods of time.
Diminished sodium delivery to the distal sites of potassium secretion is commonly cited as a cause of hyperkalemia. However, this explanation is not sufficient unless urinary sodium excretion markedly falls to levels below 10 to 20 mEq/day; sodium delivery to the distal tubule, the major site of potassium secretion, is rarely rate-limiting, even when dietary sodium intake is markedly reduced [3] . Furthermore, recent studies suggest that flow, rather than sodium delivery, may be the primary determinant of potassium secretion [9] . In the patient we are discussing, neither decreased sodium excretion nor decreased urine flow were present and thus cannot account for the development of hyperkalemia.
The patient did have moderate chronic renal insufficiency secondary to a combination of 'sickle cell" kidney disease, nephrosclerosis, gouty nephropathy, and as we will see later, mesangiocapillary glomerulonephritis. However, it is uncommon for a patient with chronic renal failure to have hyperkalemia unless the glomerular filtration rate is less than 10 to 15 mllmin. Such patients are protected from hyperkalemia by a remarkable adaptive increase in potassium secretion by the remaining renal tubular cells [13] [14] [15] , enhanced gastrointestinal potassium secretion [16] , and increased movement of potassium into tissues [17, 18] .
None of the previously discussed abnormalities can explain this patient's hyperkalemia; one must consider therefore the possibility of either a defect in the renin-angiotensin-aldosterone axis or a primary tubular potassium secretory defect. In previously published studies from our laboratory, we demonstrated impaired potassium excretion in patients with sickle cell disease who had normal aldosterone secretion [19] . Thus, on a priori grounds, a primary defect in renal tubular potassium secretion seemed the most likely cause of hyperkalemia in this patient. We studied 6 patients with sickle cell disease who ranged in age between 19 and 37 years; all were normokalemic and had normal inulin and para-aminohippurate clearances. In these individuals, the increase in urinary potassium excretion following the intravenous administration of potassium chloride, furosemide, and sodium sulfate was markedly impaired. This impairment occurred despite normal basal aldosterone levels and a normal plasma aldosterone response to volume contraction, ambulation, ACTH, and angiotensin II [19] . Impaired potassium secretion in the presence of an intact renin-aldosterone axis is evidence of a renal tubular defect in potassium secretion. The inability to augment potassium excretion after intravenous sodium sulfate administration is particularly characteristic of a renal tubular secretory defect. Delivery of the impermeant sulfate anion, which significantly increases the negativity within the lumen, markedly increases potassium secretion in normal individuals, and this stimulatory effect, although somewhat blunted, persists in the absence of aldosterone [20, 21] . Despite these findings, clinically significant hyperkalemia is an exceptional occurrence in patients with sickle cell disease [22] . On the basis of histologic changes in the papilla and medulla [5] [6] [7] , however, one might anticipate that hyperkalemia would occur if such patients lived long enough for the renal lesion to progress.
To examine whether a tubular defect in potassium secretion was present in this patient, he was given an intravenous infusion of sodium sulfate (1.8 mmoles/kg over 2 hours). The increase in urinary potassium excretion was determined over the subsequent 6 hours ( Fig. 2A) . Baseline urinary potassium excretion was 55 pEq/min and increased to a maximum of only 73 .tEq/min as compared with a greater than twofold increase in control patients. The response to furosemide was also markedly blunted (Fig. 2B ). This agent increases urinary potassium excretion by augmenting aldosterone secretion, by increasing both distal sodium delivery and tubular fluid flow. The latter two factors are not de- pendent on an increase in aldosterone. The blunted response to both sodium sulfate and furosemide in this patient indicates a primary renal tubular potassium secretory defect similar to that found in the 6 patients with sickle cell disease described previously before [19] .
But the patient we are considering here presents an even more complicated picture, because a defect in the renin-aldosterone axis also was found. In this individual, the aldosterone response to angiotensin II was blunted, and no increase in plasma aldosterone occurred following ACTH administration (Table 2) . Following volume contraction with furosemide and ingestion of a low-sodium diet, the plasma aldosterone response approximated that of normal controls (Table 3 ), but the plasma potassium concentration at this time was 6.5 mEq/liter. Since a Control values represent the mean SEM. hyperkalemia is the most potent stimulus to aldosterone secretion on a chronic basis [11] , when this patient's plasma aldosterone response is viewed in light of the prevailing plasma potassium concentration, aldosterone secretion is deficient. The defect in aldosterone secretion became more obvious when the subject was ambulated for 2 hours following volume depletion. In contrast to the control subjects in whom the plasma aldosterone concentration rose from 26 to 66 nglml, no increase was observed in this patient. With regard to plasma renin activity, both the baseline as well as the stimulated values were markedly diminished as compared with those of age-matched controls (Table 3) . Thus, the patient we are discussing here might be considered to have hyporeninemic hypoaldosteronism" [23] . It should be pointed out, however, that the plasma a!-dosterone response to both angiotensin II and ACTH, substances known to directly stimulate a!-dosterone secretion [24, 25] , was impaired. Most importantly, persistent hyperkalemia, which normally provides a potent stimulus to aldosterone secretion [11], also failed to enhance its secretion.
These observations suggest that, even though hyporeninemia was present, defects at the level of aldosterone biosynthesis, aldosterone release, or both may have contributed importantly to the hypoaldosteronism in this patient. Before returning to the question of defective aldosterone secretion, I would like to review the literature on the syndrome of hyporeninemic hypoaldosteronism."
Review of hyporeninem ic hypoaldosteronisn. To date, 81 cases of this syndrome have been reported in the English literature . The clinical findings are quite typical ( Table 4 ). The mean age is 65 7 years, with a range from 32 to 82 years. This observation may be important, as both renin and a!-dosterone secretion are known to diminish with advancing age. Approximately 75% of the patients are asymptomatic, and hyperkalemia is discovered on routine laboratory screening or during studies for an unassociated illness. The remainder of the patients come to medical attention because of symptoms referable to the hyperkalemia, such as muscle weakness or cardiac arrhythmias. Hyperchioremic metabolic acidosis is found in about 50% of the patients. Salt wasting is distinctly uncommon; most patients have a partial defect in aldosterone secretion, but their plasma aldosterone levels, although reduced, are sufficient to maintain normal sodium balance unless the dietary sodium intake is markedly restricted. Even though sodium balance is normal, however, the low circulating aldosterone levels are insufficient to prevent hyperkalemia. Baseline cortisol levels as well as the cortisol response to ACTH have been reported as normal in all patients.
Two underlying disorders, chronic renal failure and diabetes mellitus, are present in such high frequency in this syndrome as to preclude a chance association. Chronic renal failure was present in 57 of the 81 patients. The types of renal disease are listed in Table 5 ; diabetic glomerulosclerosis leads the list and is followed by a variety of renal diseases including interstitial nephritis, hypertensive nephropathy, presumed gouty nephropathy, nephrolithiasis, analgesic nephropathy, and some others. The syndrome also has been described in patients with glomeru!onephritis. Diabetes mellitus was present in 40 of the 81 patients. We will return to a possible link between diabetes and hypoaldosteronism later.
I noted with interest that the patient we are discussing here had hyperuricemia with clinical gout as well as chronic hypertension. But he had neither a family history nor clinical or laboratory evidence of diabetes mellitus. The fasting glucose concentration was not elevated and an intravenous glucose tolerance test was minimally abnormal, but the latter finding could easily be explained by a combination "Type unspecified C Gouty nephropathy not documented histologically of age and renal insufficiency, both of which are associated with decreased glucose tolerance. In the 81 reported patients, baseline plasma atdosterone concentrations were low or low-normal; after volume contraction, a subnormal increase occurred in all 81 ( Table 4) . None of the patients demonstrated an absolute increase close to that expected for normal subjects. Two studies examined the effect of normalization of the serum potassium concentration (by a sodium-potassium exchange resin) on plasma aldosterone secretion [51, 59] . In all 11 patients studied, plasma aldosterone levels fell significantly following reduction of the plasma potassium concentration. These results emphasize the importance of relating the plasma aldosterone level to the plasma potassium concentration. Thus, although some patients may have low-normal or even occasionally normal basal plasma aldosterone levels, these plasma concentrations must be considered abnormal in the presence of increased plasma potassium levels.
Reinterpretation of the syndrome. Although this syndrome has been called "hyporeninemic hypoaldosteronism," several lines of evidence suggest that the primary defect responsible for the hyperkalemia in many patients resides in the adrenal gland and is not related to hyporeninemia (Table 4) . First, baseline renin levels, stimulated renin levels, or both were normal in 13 of the 74 patients in whom it was measured. Thus, in at least a substantial minority of the cases, hypoaldosteronism cannot be explained on the basis of hyporeninemia. Second, the response to intravenous angiotensin II infusion was normal in only 4 of 27 patients. Since angiotensin II directly stimulates aldosterone release by the zona glomerulosa [24, 25, 62] , the response should be normal if the adrenal gland is intact. Likewise, the aldosterone response to ACTH, another agent that directly stimulates the adrenal production of aldosterone, was normal in only 7 of 34 patients. Although one could argue that more prolonged adrenal stimulation-that is, several days as opposed to a few hours-with angiotensin II and ACTH is needed to elicit a normal aldosterone response because prolonged hyporeninemia had led to disuse atrophy of the zona glomerulosa, I would counter the argument by pointing out that nephrectomized patients have normal basal aldosterone levels that increase normally following provocative stimuli even though these patients have no demonstrable circulating renin [63] [64] [65] .
These observations strongly suggest that the syndrome of "hyporeninemic hypoaldosteronism" is of mixed cause. In some patients the hypoaldosteronism is indeed secondary to hyporeninemia. In others, however, the primary defect probably resides in the adrenal gland. In the absence of sufficient circulating aldosterone, renal potassium excretion is impaired: the resulting hyperkalemia in turn suppresses renin secretion [66] [67] [68] . If this causal link is correct, prolonged normalization of the plasma potassium concentration would be expected to correct the hyporeninemia. whereas aldosterone levels would remain suppressed. Unfortunately, this important study has yet to be performed.
A third possibility is that two primary defects exist: one in the adrenal gland, leading to hypoaldosteronism, and another in the kidney, causing hyporeninemia. Resolving this issue would require a prolonged study in which the adrenal gland is stimulated for 7 to 10 days with angiotensin II, ACTH, or both. If plasma aldosterone levels did not increase despite prolonged daily administration of these agents, one could conclude that a primary adrenal defect in aldosterone secretion exists, since chronic adrenal stimulation with ACTH, angiotensin, and hyperkalemia failed to elicit an aldosterone response. Unfortunately such a study has not been done.
The hormonal and renal defects that could possibly result in hyperkalemia are summarized in Figure   3 and include: a primary renal defect leading to decreased renin secretion; a primary adrenal defect in aldosterone biosynthesis, release, or both; and a primary renal tubular potassium secretory defect. This figure also provides a possible explanation of why hyperkalemia and hypoaldosteronism are so common in diabetic patients. I should now like to turn to this problem.
Special characteristics of the diabetic. As discussed earlier, approximately one-half of the cases of "hyporeninemic hypoaldosteronism" have occurred in patients with diabetes. We know that insulin stimulates potassium uptake by a variety of tissues including muscle and liver [69] [70] [71] [72] [73] . In addition, we previously have shown that even basal insulin levels play an important regulatory role in potassium homeostasis: inhibition of basal insulin secretion by as little as 50% results in both a predictable rise in plasma potassium concentration and a decreased tolerance to exogenous potassium [12] . If insulin is also responsible for potassium uptake by the adrenal gland, then a state of intracellular potassium depletion may exist in diabetic patients (Fig. 3) . Previous studies have shown that the ability of ACTH and angiotensin II to stimulate aldosterone secretion by cultured zona glomerulosa cells is impaired in the presence of low potassium concentrations [24, 62] . These observations are consistent with the known stimulatory effect of potassium on the aldosterone biosynthetic pathway, which involves the conversions of cholesterol to deoxycorticosterone and corticosterone to aldosterone [25, 74] . Indeed, two recent reports have documented the presence of acquired enzymatic defects in aldosterone biosynthesis in diabetic patients [40, 51] . These defects involve deficiencies of both the 18-hydroxylase and 18-dehydrogenase reactions.
Whether the enzymatic defects are secondary to cellular potassium depletion or some other aspect of the diabetic state remains to be determined. Because of discrepant results regarding whether dia- In addition to the well-known glomerular changes, interstitial scarring and tubular atrophy are prominent features of diabetic nephropathy [76, 77] . Because of accelerated vascular disease, ischemic tubular injury and papillary necrosis occur with increased frequency in the diabetic population [78] . What role the development of these tubulo-interstitial lesions might play in impaired potassium excretion is unclear. However, correction of hyperkalemia in diabetic patients often requires very large doses of mineralocorticoids, and reduced tubular responsiveness thus becomes suspect. We recently examined the ability of 4 normokalemic patients with long-standing diabetes to excrete an in- rate and an intact renin-aldosterone axis, the increase in urinary potassium excretion was significantly impaired in these individuals as compared with that in control subjects. These preliminary results, combined with the inability to augment renal potassium secretion with physiologic doses of mmeralocorticoids, raise the possibility that some diabetic patients might have a primary defect in tubular potassium secretion. Finally, Schindler and Sommers have postulated that in the diabetic patient, selective damage to the juxtaglomerular apparatus by the angiopathic process might lead to a state of hyporeninemia [79] . Of course, this hypothesis does not explain the lack of adrenal responsiveness to chronic hyperkalemia, angiotensin II, and ACTH in many diabetics.
Recently Day et al and deLeiva et al suggested another explanation for the high prevalence of hyperkalemia in diabetic patients [51, 80] . These authors identified an association between high concentrations of the inactive renin precursor "big renm" and reduced levels of plasma renin activity in diabetic patients (Table 7) . This finding raises the possibility that the hyporeninemia might result from the impaired conversion of prorenin, or "big renm," to active renin.
Decreased circulating levels of catecholamines and autonomic neuropathy also have been postulated as causes of hyporeninemia in diabetic patients (Table 7) . Sympathetic nerve terminals have been demonstrated in the juxtagiomerular apparatus [81] , and epinephrine has been shown to stimulate renal secretion [82] . Because autonomic neuropathy is common in diabetes, and because patients with long-standing diabetes have decreased circulating levels of catecholamines [83] , decreased sympathetic activity has been postulated as a cause of the hyporeninemia. Support for this hypothesis comes from a recent report by Tuck et al, who found a decreased plasma renin response to isoproterenol in 5 hyperkalemic diabetics who had hyporeninemic hypoaldosteronism" as well as autonomic or peripheral neuropathy or both [84] . However, plasma and/or urinary catecholamines were normal in all 6 previously studied patients with "hyporeninemic hypoaldosteronism" [34, 35, 43, 44] , and no relation between decreased plasma epinephrine levels and defects in the renin-aldosterone axis was detected in 59 diabetic patients [75] . It seems possible nevertheless that, at least in some diabetics, decreased sympathetic nervous system activity, low circulating plasma epinephrine levels, or both might contribute to hyporeninemia. How frequently this mechanism is responsible, however, remains to be determined.
Other possible explanations jr renin suppression. Oh et al postulated that extracellular fluid volume expansion secondary to sodium retention is responsible for a state of physiologic renin suppression in the hyporeninemic hypoaldosteronism" syndrome [46] . However, none of the patients reported showed a normal aldosterone response to volume contraction that had been induced with diuretics, a low-sodium diet, or both. A two-to threefold increase in plasma aldosterone levels was observed in many patients, but the absolute values were always well below those reported in healthy controls with an equivalent degree of volume contraction. Oh et al reported patients whose plasma renin activity rose into the normal range following volume contraction for 3 to 6 weeks, but whose plasma aldosterone levels, although significantly increased, remained below normal. The disproportionate increase in plasma renin as compared to plasma aldosterone levels in this study is another observation that points to a primary adrenal defect in aldosterone secretion.
Finally, decreaed circulating concentrations of prostaglandins have been suggested as a cause of hyporeninemic hypoaldosteronism." Prostaglandin E2 is known to stimulate renin release [85] ; the administration of prostaglandin synthesis inhibitors impairs renin release [86, 87] . Some prostaglandins, E1 and E2, also stimulate aldosterone and corticosterone synthesis in vitro [88] . Recently, hyperkalemia was observed in association with hyporeninemia and hypoaldosteronism in a 28-year-old woman treated with indomethacin [89] . Both the hyperkalemia and the impairment of the renin-aldosterone axis were corrected after withdrawal of indomethacin; both recurred when treatment with indomethacin was resumed. Two subsequent studies have demonstrated diminished urinary prostaglandin E levels in patients with the "hyporeninemic hypoaldosteronism" syndrome [58, 90] , but this observation has been refuted by other reports [91, 92] . Although the possible association between prostaglandin deficiency and hyporeninemic hypoaldosteronism" is interesting, further studies are needed to clarify these conflicting observations. Management of hyperkalernia. Once the diagnosis of hypoaldosteronism has been established, several different therapeutic regimens can be employed to lower the plasma potassium concentration. The physician should keep in mind, however, that the majority of patients suffering from this syndrome are elderly and have associated medical complications such as diabetes mellitus, atherosclerotic cardiovascular disease, chronic renal failure, and hypertension. Caution should be taken therefore to ensure that the side effects of therapy do not outweigh the benefits of correcting the hyperkalemia. Mineralocorticoid replacement, usually given as fludrocortisone acetate, is the mainstay of therapy (Table 8) . Studies of 51 patients treated with a mmeralocorticoid report a reduction of the plasma potassium concentration in 43, but large doses of the steroid, often as high as 0.4 to 1.0 mg daily, were frequently required to reduce the plasma level to normal . As indicated above, this observation suggests that the renal tubular cell is resistant to the action of mineralocorticoids, at least with respect to their effect on potassium secretion. Sensitivity to the sodium-retentive effects of fludrocortisone appeared to be less affected, because marked sodium retention with edema, exacerbation of hypertension, and congestive heart failure were common consequences. In many patients the administration of a loop diuretic was required to prevent or treat these complications.
The patient presented today underwent a trial of deoxycorticosterone acetate (DOCA), 10 mg twice a day, under metabolic balance conditions; the results of treatment are shown in Figure 4 . The dotted lines represent the dietary sodium and potassium intake. During the 3 days prior to DOCA administration, the plasma potassium concentration was 6.3 mEq/liter, and the potassium excretion in both the urine and stool approximated the dietary potassium intake. Following DOCA administration, the plasma potassium concentration fell to 5.2 mEq/liter, but this improvement was associated with a weight gain and a worsening of hypertension. Because of the plasma potassium response to DOCA, the patient was started on fludrocortisone acetate; at a dose of 0.4 mglday the potassium concentration ranged from 4.9 to 5.2 mEq/liter. However, treatment was again associated with marked sodium retention and a 7 kg weight gain that was difficult to control even with large doses of furosemide. Finally, fludrocortisone was discontinued because the patient developed congestive heart failure. An interesting aspect of this patient's initial response to DOCA was that his plasma potassium concentration fell without a significant increase in net potassium excretion. Urinary potassium excretion did increase slightly on DOCA, but this small increase could not account for the progressive decline in the plasma potassium concentration. More importantly, the net potassium balance did not change; this finding suggests that the mineralocorticoid primarily increased the movement of potassium from the extracellular to the intracellular compartment.
Four previous reports also document correction of hyperkalemia by mineralocorticoid therapy in patients with "hyporeninemic hypoaldosteronism" without a concomitant increase in urinary potassium excretion [32, 33, 54, 58] . This observation is consistent with the known effect of aldosterone on extrarenal potassium homeostasis [93, 94] . These reports and the response of the patient under discussion underscore the existence of tubular unresponsiveness, which has not previously been emphasized in this syndrome. Whether this tubular defect in potassium secretion is related to the underlying renal disease in most of these patients or to some other as yet unrecognized factor remains to be determined.
If the hyperkalemia fails to respond to fludrocortisone acetate or if excessive sodium retention is encountered, a trial of potassium-wasting diuretics is warranted. In many patients, particularly those with a primary tubular potassium secretory defect, thiazide diuretics are effective [95] . Sodium bicarbonate may improve potassium excretion and correct the hyperkalemia in some patients. In this setting, the kaliuresis is probably caused by many factors including increased luminal negativity of the distal tubule. The presence in the lumen of the poorly reabsorbable bicarbonate anion, increased delivery of sodium to the distal tubule, and a direct stimulatory effect of alkalosis on distal potassium secretion all combine to produce the kaliuresis. The increase in blood pH and bicarbonate concentration also helps shift potassium into cells. If these measures fail, one can always employ a sodium-potassium exchange resin such as sodium polystyrene sulfonate. In my experience, however, most patients have found this medication difficult to tolerate. In many patients, particularly those with only mild to moderate hyperkalemia, 5.0 to 5.6 mEqiliter, it is often best to institute no therapy and periodically check the plasma potassium concentration to ensure that the hyperkalemia has not reached dangerous levels. In all patients, drugs known to impair renal potassium excretion should be avoided (Table  8) . Volume contraction, which decreases distal sodium delivery, also should be prevented. A speculative thought. There are many other interesting features of this case, but rather than try to consider them all, I would like to end on a provocative note and propose still another explanation for the hyperkalemia in this patient. The patient recently succumbed at age 71 from a massive stroke. Postmortem examination of the kidneys revealed large glomeruli containing sickled red blood cells. An increase in mesangial cellularity and mesangial matrix was present, with thickening of the capillary loops, extensive interstitial fibrosis, and tubular atrophy. Electron microscopy revealed thickened glomerular basement membranes with electron-dense deposits and mesangial proliferative changes. Numerous electron-dense deposits within the tubular basement membranes were apparent also (Fig. 5) . These pathologic findings are similar to those reported by Pardo et al., who studied 7 patients with sickle cell disease and found renal tubular antigen-antibody complexes in the plasma and kidneys [96] . I wonder whether it is possible that this patient's impairment of renal tubular potassium secretion resulted from antibodies directed at the tubular basement mem-:
•7cç 'ic-. gy Division, University Hospital, Boston, Massachusetts): As you suggested, it appears that at least some cases of hypoaldosteronism are due to a primary adrenocortical disorder. As you know, our own observations in colloboration with the Christlieb group at the Joslin Clinic suggest that at least 2 patients have had primary corticosterone methyl oxidase deficiencies [51] . One patient appeared to have corticosterone methyl oxidase deficiency Type I in which the precursor, corticosterone, was overabundant. In the other patient, who had corticosterone methyl oxidase deficiency Type II, the by-product, 1 8-hydroxycorticosterone, appeared in excess. The defect can be amplified markedly by the administration of ACTH. We wondered whether the presence of big renin had anything to do with the biosynthetic defects we observed, but thus far we have been unable to relate circulating levels of big renin to inhibition of the enzymes involved in the oxidation of corticosterone to aldosterone.
The role of potassium is even more difficult to explain in patients with hypoaldosteronism. Potassium stimulates aldosterone biosynthesis at both an early and a late stage. There is also some suggestion that potassium stimulation of the conversion of cholesterol to aldosterone precursors is unimpaired in hypoaldosteronism but that potassium stimulation of corticosterone methyl oxidation is impaired. DR. DEFRONZO: One of the ways to answer that question would be to culture zona glomerulosa cells in the presence of insulin to define whether potassium uptake is insulin dependent as it is in muscle and liver tissue. If it is, I think one could argue strongly that in the absence of insulin, a state of intracellular potassium depletion exists and that this depletion could account for the abnormalities in aldosterone biosynthesis observed in vivo [25, 74] . DR. COHEN: You stated that in studies with cultured zona glomerulosa cells, the low potassium concentration counteracted the stimulation of a!-dosterone secretion by angiotensin II and ACTH.
Were those studies performed in the absence of insulin? If so, doesn't that suggest that the potassium entry step is not dependent on insulin? DR. DEFRONZO: Yes, those studies were carried out in the absence of insulin. However, if one examines the dose-response curve, one finds that obtaining a maximum aldosterone response to angiotensin II and to ACTH requires concentrations of potassium greater than 5 mEq/liter [24, 62] . Perhaps if insulin were added to the medium, a maximum response could be achieved with concentrations in the physiologic range.
I would like to ask Dr. Melby a question. Do you think that prostaglandin deficiency plays any role in the impaired renin-aldosterone response in this heterogeneous group of patients? Recently, several reports have appeared that suggest a role for prostaglandin E deficiency in this syndrome [58, 89, 90] . What is known about the effects of prostaglandin on the enzymatic steps involved in steroidogenesis?
DR. MELBY: We have found no evidence for this except in one paper by Saruta and Kaplan, who found that prostaglandins affect aldosterone secretion; in that study, superphysiologic amounts of PGE2 were used [99] . I would like to suggest another explanation.
Recently, many papers have examined the regulation of adrenal aldosterone secretion by dopamine. Dopamine tonically inhibits aldosterone secretion, and receptors for dopamine are present in the adrenal cortex. As a matter of fact, in some patients with autonomic insufficiency, the dopamineto-norepinephrine ratio changes. Whether dopamine excess is involved in hypoaldosteronism I don't know, but it is tempting to speculate about it. The prostaglandin question is confusing. As I understand it, prostaglandin deficiency would probably lead to decreased renin secretion and not directly affect aldosterone secretion.
DR. DEFRONZO: I can't comment directly on the role of dopamine, but there is some additional new information on the effect of prostaglandins on the renin-angiotensin system. Tan and Muirow examined the ability of furosemide to stimulate plasma renin activity and plasma aldosterone secretion in a group of normal volunteers before and after receiving indomethacin, a prostaglandin synthetase inhibitor [100] . A marked inhibition of both the renin and aldosterone response was found. On the basis of these studies, the authors postulated that prostaglandin deficiency plays an important role in the syndrome of hyporeninemic hypoaldosteronism. It is unclear, however, whether the changes were due to a vascular phenomenon or to inhibition of some enzymatic step in renin biosynthesis, aldosterone biosynthesis, or both. First, I thoroughly support your idea that many factors are involved in the pathogenesis of hyporeninemic hypoaldosteronism. I also concur with your observations that large doses of mineralocorticoids are often necessary in the treatment of these patients. As you pointed out, many patients get into difficulty because of sodium excess when treated indiscriminately with fludrocortisone, and the drug therefore must be used with great caution. Second, I would like to know whether there are sufficient data in normal individuals, especially data corrected for age, that enable one to interpret renin and aldosterone values under a variety of conditions. The published literature does not have a great deal of information on this.
DR. DEFRONZO: In answer to Dr. Sawin's question, I would like to note that the controls for all of the studies discussed today were age-matched. In our study of potassium homeostasis in patients with sickle cell disease, the mean age of the control population was 23 years and was similar to that of the sickle cell patients [19] . Furthermore, for all comparisons with the patient discussed today, a separate group of older individuals was used to establish control values. So, I think it is safe to say that renin levels decrease as a function of age but the values in this elderly patient were even lower than in agematched controls.
DR. SAwIN: One final question-You pointed out that this patient had a substantial rise in his aldosterone level following volume contraction but that it did not rise as much as in normal controls. Did the serum potassium level change during that interval? DR. DEFRONZO: The serum potassium level fell slightly, from 6.7 to 6.5 mEq/liter. This was probably due to the administration of furosemide, which was used to induce the volume contraction. In most of the reported cases of hyporeninemic hypoaldosteronism, plasma renin and aldosterone levels rose following volume contraction, but the rise is markedly blunted. In one study, the aldosterone level rose by two-to threefold and it was defined as a normal response [46] . However, since the basal plasma aldosterone level was very low, the absolute increase in plasma aldosterone concentration was significantly impaired as compared to normal controls. In this situation, I think it is misleading to look at the percentage increase in plasma aldosterone above the basal level rather than at the absolute values.
DR. W. B. SCHWARTZ (Professor of Medicine, Tufts University School of Medicine): How likely do you think it is that an atrophic adrenal gland might not respond to acute stimulation but might respond after several days of stimulation? DR. DEFRONZO: I think this is a possibility that needs to be examined, as I tried to emphasize in my discussion. To prove that the aldosterone response to angiotensin II and to ACTH is blunted, those hormones should be given for at least 3 to 4 consecutive days. However, I would like to emphasize that the most potent stimulus to aldosterone secretion when present on a chronic basis is hyperkalemia. McCaa et al. have shown that if you increase the serum potassium level by as little as 0.3 to 0.5 mEq/liter, aldosterone levels will increase significantly and will remain elevated despite a return of the serum potassium concentration to normal [11] . The patient today had a serum potassium level that was persistently elevated to greater than 6 mEq/liter, yet his aldosterone response was still impaired.
DR. SCHWARTZ: Would you say therefore that it is extremely unlikely that even sustained ACTH or angiotensin II administration would produce an increase in aldosterone secretion? DR. DEFRONZO: I think that in those patients in whom the defect lies in the adrenal gland, it will not make any difference how much ACTH or angiotensin II is given. However, one might expect a different result if the defect is secondary to impaired renin secretion. Here, chronic stimulation with angiotensin II or ACTH might be necessary to elicit a normal aldosterone response. DR. COHEN: That seems inconsistent to me. If the problem were at the level of secretion and if the adrenal glands were inherently normal, why wouldn't the persistent hyperkalemia stimulate aldosterone secretion? DR. DEFRONZO: I don't know, unless, of course, multiple defects exist, as I suspect. DR. MELBY: We are studying a large number of individuals from Amish families in Hershey, Pennsylvania. One infant of one of these families has clinically evident hypoaldosteronism with salt wasting and hyperkalemia [101] . He has an inherited corticosterone methyloxidase deficiency Type II, with elevated blood 18-hydroxycorticosterone levels and depressed plasma aldosterone levels. The defect is probably inherited in an autosomal recessive fashion. These patients might compensate for their deficiency by raising their renin activity. As these patients are only occasionally hyperkalemic, I believe that multiple defects must be involved because of this ability to compensate. DR. DEFRONZO: Your findings are similar to what has been described in Iranian Jews, in whom a partial aldosterone biosynthetic defect also appears to be present [102] . Those patients have normal plasma aldosterone concentrations at the expense of markedly elevated plasma renin levels. They can excrete their daily intake of potassium normally but they require increased plasma potassium levels to do so. DR. COHEN: Hyponatremia is another potent stimulus to aldosterone secretion [103] , which might in theory be used as a provocative test. Do you know whether anyone has ever attempted to use this stimulus to evaluate adrenal function? DR. DEFRONZO: From a practical standpoint that would be difficult because one would have to decrease the serum sodium concentration by at least 10 mEq/liter to stimulate aldosterone secretion [104] . I think that this would be difficult to carry out without changing the volume status of the patient. As far as I know, hyponatremia has not been used as a provocative stimulus. DR. DEFRONZO: Of the 81 patients reported with this syndrome, adrenal histology has been looked at in 5. In one patient, the adrenal was described as atrophic, but in none were any significant histologic changes observed by light microscopy. I do not know of any reports describing abnormalities in adrenal pathology in patients with sickle cell disease, but this question has not been examined in a systematic fashion.
DR. MARK MOLITCH (Endocrinology Division, NEMCH): You mentioned that impaired tubular potassium secretion might occur in patients with lupus nephritis. Have you seen any patients with lupus who had hyporeninemic hypoaldosteronism? DR. DEFR0NzO: No, the two patients that we reported previously both had normal renin and aldosterone responses. However, both had an impaired ability to augment potassium excretion in response to sodium sulfate and furosemide [98] . DR. M0LITcH: We have been interested in a small number of patients who develop a modest hyperchloremic acidosis in the recovery phase following ketoacidosis. I wonder whether those patients have renal tubular disease or hyporeninemic hypoaldosteronism, perhaps due to volume overload in the recovery period. DR. DEFRONZO: Oh et a!. reported the frequent development of hyperchloremic acidosis during the treatment of 35 diabetic patients with ketoacidosis [105] . They did not directly examine renal acidification, however. One well-documented case of hyperkalemia and hyporeninemic hypoaldosteronism developing secondary to volume overload has been reported [106] . That patient consumed massive doses of sodium bicarbonate as baking soda for epigastric discomfort and developed hyperkalemia. When the sodium bicarbonate therapy was stopped, the plasma renin and aldosterone levels, which were low, rose and the hyperkalemia disappeared. The authors postulated that the chronic state of volume expansion was responsible for the aldosterone and renin suppression. I think this is an uncommon occurrence, however.
DR. KASSIRER: Long before the syndrome of hyporenine mic hypoaldosteronism was described, we recognized patients with mild renal insufficiency who had hyperchioremic acidosis and hyperkalemia. Typically these patients had some form of tubulointerstitial renal disease. What is your opinion of such patients, that is, nondiabetics with mild renal insufficiency? Do some have renal tubular disease only and others have hyporeninemic hypoaldosteronism?
DR. DEFRONZO: I do think that these patients fall into two separate groups. In some, renal interstitial disease results in tubular injury and a permanent tubular defect in potassium and hydrogen ion secretion despite normal plasma renin and aldosterone levels. In others, a so-called Type IV renal tubular acidosis is probably present. In this latter group, it has been postulated that an interstitial disease process injures the juxtaglomerular apparatus leading to hyporeninemia and eventually to hypoaldosteronism. The development of hypoaldosteronism is responsible, then, for the defect in both potassium and hydrogen ion secretion. In this context, the acid-base status of patients with hyporeninemic hypoaldosteronism is of interest. Of the published cases, approximately one-half have hyperchioremic metabolic acidosis. The data in the literature concerning the influence of aldosterone on renal acidification are somewhat controversial [57, 107] . Sebastian et al. treated 4 such patients with fludrocortisone and reported that renal acidification returned to normal and that the hyperchloremic acidosis was corrected [57] . DR. COHEN: I think that study is hard to interpret. When those patients were given fludrocortisone, they were also ingesting a normal salt diet and hence almost certainly experienced positive sodium balance. We know from studies of chronic hydrochloric acid acidosis in the dog that DOCA-induced volume expansion stimulates acid excretion but that DOCA alone-that is, without volume expansiondoes not [108] .
DR. DEFRONZO: A recent study by Hulter et al. has examined the role of aldosterone in renal acidification in a more controlled fashion utilizing the adrenalectomized dog model [109] . The authors conclude that a lack of aldosterone leads to an impairment in renal acidification and ammonia excretion.
DR. A. LEVEY (Renal Fellow, NEMCH): Do you think that this patient's sympathectomy played any role in the genesis of the hyperkalemia? DR. DEFRONZO: It is likely that the sympathetic nervous system is important in maintaining basal renm levels. Also, it is known that catecholamines are a provocative stimulus for renin secretion. Thus, I think the sympathectomy could have played some role in the development of the hyporeninemia. Although the sympathectomy was performed long before the hyperkalemia developed, nevertheless it may have been an underlying factor just as age was. The role of the sympathetic nervous system and decreased circulating epinephrine levels in the development of the hyporeninemic hypoaldosteronism syndrome clearly deserves to be examined in a more systematic pattern. 
